Virus-like particle vaccine by intranasal vaccination elicits protective immunity against respiratory syncytial viral infection in mice

Cai, Mengying; Wang, Cheng; Li, Yufeng; Gu, Huiying; Sun, Sujing; Duan, Yueqiang; Chen, Lai; Wang, Keyu; Yang, Xiaolan; Li, Xing; Zhang, Peirui; Wang, Zhaohai; Zhang, Shaogeng; Guo, Xiaodong; Liu, Shubing; Tong, Yigang; Wang, Xiliang; Yang, Peng

doi:10.1093/abbs/gmw118

Cited by 22 publications

(13 citation statements)

References 27 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…showed that a combination of respiratory syncytial virus (RSV) fusion protein VLPs and glycoprotein VLPs increases protection against live RSV, with a reduction in lung viral replication and histopathology damage. 122 However, some adjuvants, such as Toll-like receptor 3, ricin toxin B, TLR7 and nine of its agonists, and murabutide, need to be applied to increase the immune response of VLP vaccines. 123-126 Following i.n.…”

Section: Preclinical Evaluation Of Intranasal Vaccinationmentioning

confidence: 99%

Noninvasive vaccination against infectious diseases

Zheng

Díaz-Arévalo

Guan

et al. 2018

Human Vaccines & Immunotherapeutics

View full text Add to dashboard Cite

The development of a successful vaccine, which should elicit a combination of humoral and cellular responses to control or prevent infections, is the first step in protecting against infectious diseases. A vaccine may protect against bacterial, fungal, parasitic, or viral infections in animal models, but to be effective in humans there are some issues that should be considered, such as the adjuvant, the route of vaccination, and the antigen-carrier system. While almost all licensed vaccines are injected such that inoculation is by far the most commonly used method, injection has several potential disadvantages, including pain, cross contamination, needlestick injury, under- or overdosing, and increased cost. It is also problematic for patients from rural areas of developing countries, who must travel to a hospital for vaccine administration. Noninvasive immunizations, including oral, intranasal, and transcutaneous administration of vaccines, can reduce or eliminate pain, reduce the cost of vaccinations, and increase their safety. Several preclinical and clinical studies as well as experience with licensed vaccines have demonstrated that noninvasive vaccine immunization activates cellular and humoral immunity, which protect against pathogen infections. Here we review the development of noninvasive immunization with vaccines based on live attenuated virus, recombinant adenovirus, inactivated virus, viral subunits, virus-like particles, DNA, RNA, and antigen expression in rice in preclinical and clinical studies. We predict that noninvasive vaccine administration will be more widely applied in the clinic in the near future.

show abstract

Section: Preclinical Evaluation Of Intranasal Vaccinationmentioning

confidence: 99%

Noninvasive vaccination against infectious diseases

Zheng

Díaz-Arévalo

Guan

et al. 2018

Human Vaccines & Immunotherapeutics

View full text Add to dashboard Cite

show abstract

“…and intranasal (i.n.) delivery (8)(9)(10)(11). These vaccines appear to elicit both strong antibody responses and long-lived and polyfunctional CD4 ϩ T cell responses (12).…”

mentioning

confidence: 99%

A Single Intramuscular Dose of a Plant-Made Virus-Like Particle Vaccine Elicits a Balanced Humoral and Cellular Response and Protects Young and Aged Mice from Influenza H1N1 Virus Challenge despite a Modest/Absent Humoral Response

Hodgins

Yam

Winter

et al. 2017

Clin Vaccine Immunol

View full text Add to dashboard Cite

Virus-like-particle (VLP) influenza vaccines can be given intramuscularly (i.m.) or intranasally (i.n.) and may have advantages over split-virion formulations in the elderly. We tested a plant-made VLP vaccine candidate bearing the viral hemagglutinin (HA) delivered either i.m. or i.n. in young and aged mice. Young adult (5-to 8-week-old) and aged (16-to 20-month-old) female BALB/c mice received a single 3-g dose based on the HA (A/California/07/2009 H1N1) content of a plant-made H1-VLP (i.m. or i.n.) split-virion vaccine (i.m.) or were left naive. After vaccination, humoral and splenocyte responses were assessed, and some mice were challenged. Both VLP and split vaccines given i.m. protected 100% of the young animals, but the VLP group lost the least weight and had stronger humoral and cellular responses. Compared to split-vaccine recipients, aged animals vaccinated i.m. with VLP were more likely to survive challenge (80% versus 60%). The lung viral load postchallenge was lowest in the VLP i.m. groups. Mice vaccinated with VLP i.n. had little detectable immune response, but survival was significantly increased. In both age groups, i.m. administration of the H1-VLP vaccine elicited more balanced humoral and cellular responses and provided better protection from homologous challenge than the splitvirion vaccine.KEYWORDS aged-mouse model, influenza, virus-like particles (VLPs), plant-made vaccines A ccording to the World Health Organization, influenza epidemics account for 250,000 to 500,000 deaths worldwide every year (http://www.who.int/mediacentre/factsheets/ fs211/en/). Although vaccines are widely recommended to protect against influenza, the elderly often respond poorly, in part due to prior experience with influenza virus antigens (Ag) (1), but also as a result of immunosenescence (2). The latter affects both innate and adaptive immune responses and has broad implications for both natural infection and vaccination (1, 2).Influenza vaccines for adults are administered by either intramuscular (i.m.) or intradermal injection of detergent-split virions at a fixed dose of 15 g hemagglutinin (HA)/strain (3). These vaccines typically elicit strong antibody responses in healthy young adults and achieve vaccine efficacy (VE) that varies between strains and years but averages 50 to 60% (4). These formulations work less well in the elderly (5

show abstract

“…Cai et al generated VLPs with influenza virus (IFV) M1 matrix protein and RSV F or RSV G protein. Both the F and G vaccines were effective at creating specific antibodies against RSV and protected mice against RSV challenge [35]. There is some debate over using either pre- or post-fusion F protein conformation.…”

Section: Virus-like Particles (Vlp)mentioning

confidence: 99%

Respiratory Syncytial Virus Vaccine Approaches: a Current Overview

Clark

Guerrero-Plata

2017

Curr Clin Micro Rpt

View full text Add to dashboard Cite

Purpose of Review Respiratory syncytial virus (RSV) is a global human pathogen responsible for lower respiratory tract infections (LRTI). While RSV infection is innocuous in healthy adults, it is the leading cause of infant hospitalization for respiratory tract infection. Nearly everyone shows evidence of an RSV infection by the age of 3. However, there is still not a vaccine commercially available. This review will provide an update on the clinical and preclinical vaccine studies and different approaches to prevent RSV infection. Recent Findings Novel vaccine approaches that induce protection against RSV without enhancement of respiratory tract disease. Summary Recent technological approaches have led to generation of different strategies to prevent RSV infection, including live attenuated, chimeric, and subunit vaccines, virus-like particles, and nanoparticles. These vaccine approaches represent promising candidates towards an efficient RSV vaccine that effectively protects infants, children, and adults.

show abstract

Virus-like particle vaccine by intranasal vaccination elicits protective immunity against respiratory syncytial viral infection in mice

Cited by 22 publications

References 27 publications

Noninvasive vaccination against infectious diseases

Noninvasive vaccination against infectious diseases

A Single Intramuscular Dose of a Plant-Made Virus-Like Particle Vaccine Elicits a Balanced Humoral and Cellular Response and Protects Young and Aged Mice from Influenza H1N1 Virus Challenge despite a Modest/Absent Humoral Response

Respiratory Syncytial Virus Vaccine Approaches: a Current Overview

Contact Info

Product

Resources

About